The absorption of non-haem iron during suppression of gastric acid secretion - The absorption of non-haem iron and gastric acid

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a hemochromatosis patient must meet all of the following criteria:
•Patients with hereditary hemochromatosis, homozygous for C282Y, with biochemical or liver biopsy proven iron overload in the past.
•Patients are currently on maintenance treatment of which the last treatment was more than six weeks ago.
•Ferritin levels for men and postmenopausal women should be < 400 ug/l and for premenopausal women <150 ug/l, for at least 3 months.
•Age: > 18 years, <=65;A healthy control must meet all the following criteria:
•Subjects do not have HFE mutations
•Age >18, <=65
•Ferritine levels for men and postmenopausal women should be < 400 ug/l and for premenopausal women <150 ug/l.

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•Patients/subjects with known acute or chronic inflammatory disorders, such as inflammatory bowel disease or rheumatoid arthritis, hepatitis B, hepatitis C or HIV infection
•Patients/subjects with cirrhosis of the liver
•Patients/subjects with excess alcohol ingestion (> 21 glasses a week for men, >14 glasses a week for women)
•Phlebotomy/erythrocytapharesis less than 6 weeks before participation in research
•Patients/subjects <18 years, and >65 years
•Patients/subjects with a malignancy
•Patients/subject who are anemic
•Patients/subjects already on PPI treatment
•Patients/subjects who experienced side effects of PPI*s
•Patients/subjects on different acid-suppressing medication (e.g. H2- blockers)
•Patients/subjects that use iron supplements
•Patients/subjects who are pregnant.
•Patients/subjects who use medication that interferes with PPI medication.

发起方

Medisch Universitair Ziekenhuis Maastricht